- Optimi Health Corp. (OPTI) has acquired a diverse catalog of psilocybin and functional mushroom strains
- They are intended for cultivation in Optimi’s EU-GMP-compliant facility in Princeton, British Columbia
- The acquisition includes 24 psychedelic and nine functional strains, providing Optimi one of the largest genetic banks in the sector
- Formulated psychedelic strains will be made available to licensed researchers
- Optimi Health is a homegrown company producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets
- Shares of Optimi Health Corp are up 5.88 per cent, trading at $0.27 at 10:55 am ET
Optimi Health (OPTI) has acquired a catalog of psilocybin and functional mushroom strains.
These mushroom strains are intended for cultivation in the company’s 20,000 square foot, EU-GMP-compliant facility in Princeton, British Columbia.
The acquisition includes 24 psychedelic and nine functional strains, providing Optimi one of the largest genetic banks in the sector.
Formulated psychedelic strains will be made available to licensed researchers, Canada’s Special Access Program (SAP), as well as being utilized for on-site research in Optimi’s recently expanded analytical laboratory.
The functional strains will be optimized for the company’s growing whole body, natural supplement brand, Optmini Life.
As a leading cultivator of natural EU-GMP psilocybin, Optimi will begin processing its genetics for supply to patients requesting natural product.
Further, this acquisition will strengthen Optimi’s position as a tier-one ingredient supplier of naturally occurring psilocybin to approved entities engaging in molecular development and clinical trials.
“From the data available so far, we can say with relative certainty that psychedelic research and any novel psilocybin-assisted therapies that may result are not going to be a one-size-fits-all process,” said Optimi Health Chief Science Officer Justin Kirkland.
By collating information from clinical trials, using mushrooms from both its own supply and other sources throughout the sector, Optimi is committed to working within the regulatory approval processes necessary to ensure access to those in need.
“In conjunction with the recent completion of our analytical laboratory, this acquisition is intended to position Optimi as the leading supplier of naturally-sourced psilocybin to the burgeoning psychedelic industry,” said Optimi CEO Bill Ciprick.
Optimi Health is a homegrown company producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets.
Shares of Optimi Health Corp are up 5.88 per cent, trading at $0.27 at 10:55 am ET.